BIOMARK CANCER SYSTEMS INC.
(formerly Luger Minerals Corp.)

CONDENSED INTERIM FINANCIAL STATEMENTS

For the period ended September 30, 2014

(Stated in Canadian Dollars)

(Unaudited – Prepared by Management)

NOTICE OF NO AUDITOR REVIEW OF CONDENSED INTERIM FINANCIAL STATEMENTS

Under National Instrument 51-102, if an auditor has not performed a review of the condensed interim financial statements, they must be accompanied by a notice indicating that the condensed interim financial statements have not been reviewed by an auditor.

The accompanying unaudited condensed interim financial statements have been prepared by and are the responsibility of the Company's management.

The Company's independent auditor has not performed a review of these condensed interim financial statements in accordance with standards established by the Canadian Institute of Chartered Accountants for review of condensed interim financial statements by an entity's auditor.

BIOMARK CANCER SYSTEMS INC.
(formerly Luger Minerals Corp.)
CONDENSED INTERIM STATEMENTS OF FINANCIAL POSITION
September 30, 2014 and March 31, 2014
(Stated in Canadian Dollars)
(Unaudited – Prepared by Management)

	September 30, 2014	March 31, 2014
ASSETS		
Current		
Cash	$ 96,036	$ 92,000
Deposit (Note 1)	2,000	-
Loan receivable (Note 4)	198,693	-
	296,729	92,000
Deferred finance cost (Note 6)	14,100	-
Intellectual properties (Note 5)	800,000	-
	$ 1,110,829	$ 92,000
LIABILITIES		
Current		
Accounts payable	$ 44,817	$ 1,583
Accrued liabilities	7,000	3,500
	51,817	5,083
SHAREHOLDERS' EQUITY		
Share capital (Note 6)	877,296	102,000
Commitment to issue shares (Note 6)	279,500	-
Contributed surplus (Note 6)	34,704	-
Deficit	(132,488)	(15,083)
	1,059,012	86,917
	$ 1,110,829	$ 92,000

Nature and Continuance of Operations (Note 1)
Subsequent Events (Note 10)

Approved by the Board on November 27, 2014

"*Abdulahi Mohamed*"

BIOMARK CANCER SYSTEMS INC.
(formerly Luger Minerals Corp.)
CONDENSED INTERIM STATEMENTS OF LOSS AND COMPREHENSIVE LOSS
For the three and six months ended September 30, 2014
(Stated in Canadian Dollars)
(Unaudited – Prepared by Management)

	For the three months ended September 30, 2014	For the six months ended September 30, 2014
Administrative expenses		
Accounting and audit fees	$ 1,300	$ 4,550
Consulting fees	-	10,012
Legal fees	44,800	89,662
Listing fees	45	2,670
Office and miscellaneous	5,261	10,511
Net loss and comprehensive loss for the period	$ (51,406)	$ (117,405)
Basic and diluted loss per share	$ (0.01)	$ (0.02)
Weighted average number of common shares outstanding	5,339,560	5,538,462

THE ACCOMPANYING NOTES ARE AN INTEGRAL PART OF THESE FINANCIAL STATEMENTS

BIOMARK CANCER SYSTEMS INC.
(formerly Luger Minerals Corp.)
CONDENSED INTERIM STATEMENTS OF CASH FLOWS
For the six months ended September 30, 2014
(Stated in Canadian Dollars)
(Unaudited – Prepared by Management)

	For the six months ended September 30, 2014
Operating Activities	
Net loss for the period	$ (117,405)
Changes in non-cash working capital item related to operations:	
Accounts payable and accrued liabilities	46,734
Cash used in operating activities	(70,671)
Financing Activities	
Shares issued for cash	10,000
Deferred finder's fees	(14,100)
Commitment to issue shares	279,500
Cash provided by financing activities	275,400
Investing Activities	
Deposit	(2,000)
Loan receivable	(198,693)
Cash used in investing activities	(200,693)
Increase in cash during the period	4,036
Cash, beginning of the period	92,000
Cash, end of the period	$ 96,036
Supplemental Disclosure of Cash Flow Information:	
Cash paid during the period:	
Interest	$ -
Income taxes	$ -

Non-cash Transactions – see Note 9

THE ACCOMPANYING NOTES ARE AN INTEGRAL PART OF THESE FINANCIAL STATEMENTS

BIOMARK CANCER SYSTEMS INC.
(formerly Luger Minerals Corp.)
CONDENSED INTERIM STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY
For the six months ended September 30, 2014 and
For the period from Incorporation February 27, 2014 to March 31, 2014
(Stated in Canadian Dollars)
(Unaudited – Prepared by Management)

	Number of Shares	Share Capital	Commitment to issue Shares	Contributed Surplus	Deficit	Total
Balance, at Incorporation February 27, 2014	-	$ -	$ -	$ -	$ -	$ -
Shares issued for cash at $0.005	2,000,000	10,000	-	-	-	10,000
Shares issued for cash at $0.02	4,600,000	92,000	-	-	-	92,000
Loss for the period	-	-	-	-	(15,083)	(15,083)
Balance, March 31, 2014	6,600,000	102,000	-	-	(15,083)	86,917
Shares issued for cash at $0.02	500,000	10,000	-	-	-	10,000
Shares return for cancellation	(2,200,000)	(34,704)	-	34,704	-	-
Shares issued for assets	40,000,000	800,000	-	-	-	800,000
Cash received for private placement	-	-	279,500	-	-	279,500
Loss for the period	-	-	-	-	(117,405)	(117,405)
Balance, September 30, 2014	44,900,000	$ 877,296	$ 279,500	$ 34,704	$ (132,488)	$ 1,059,012

THE ACCOMPANYING NOTES ARE AN INTEGRAL PART OF THESE FINANCIAL STATEMENTS

1. Nature and Continuance of Operations

Luger Minerals Corp. (the "Company" or "Luger") was incorporated on February 27, 2014 under the Business Corporation Act of British Columbia. The head office of the Company is 165 – 10551 Richmond, British Columbia, V6X 2W8. On October 15, 2014, the Company changed its name to Biomark Cancer Systems Inc.

Plan of Arrangement

On June 19, 2014 an Arrangement Agreement ("Arrangement") was entered into among Luger, Noor Energy Corporation. ("Noor") and Biomark Diagnostics Inc. ("Biomark Diagnostics"), and Kyle Stevenson, the controlling shareholder of Noor. ('the Controlling Shareholder").

The parties have agreed to reorganize their businesses by way of a plan of arrangement to be carried out under the provisions of the Business Corporations Act (British Columbia). As a part of the Arrangement Agreement, the following transactions will take place:

i) Luger shall acquire from Noor all of the issued and outstanding shares of Biomark Diagnostics (the "Purchase Shares") for consideration of $5,000 consisting of a deposit of $2,000 (paid) to be paid on execution of the Arrangement Agreement and the balance to be paid on closing;

ii) Biomark Diagnostics and the shareholders of Luger will complete a one-for-one share exchange pursuant to which Luger will become a wholly-owned subsidiary of Biomark Diagnostics.

iii) Noor shall issue 1,000 of its common shares to Biomark Diagnostics in exchange for 310,000 shares of Biomark Diagnostics and the Controlling Shareholder shall agree to forgo 60,000 Biomark Diagnostics shares to which he would otherwise be entitled to.

iv) The Purchase Shares and the 60,000 Biomark Diagnostics shares held by the Controlling Shareholder shall be cancelled.

Following completion of the Arrangement Agreement, Biomark Diagnostics will apply for a listing on the Canadian Securities Exchange.

As a result of the Arrangement, the shareholders of Luger will own a majority of the issued and outstanding shares of Biomark Diagnostics. Accordingly, this transaction will be accounted for as a reverse acquisition.

Completion of the transactions contemplated by the Arrangement Agreement will be subject to the approval of the shareholders and the Supreme Court of British Columbia. On October 30, 2014, the shareholders of the Company and Biomark Diagnostics executed the Arrangement.

2. Basis of Preparation

Statement of Compliance

These condensed interim financial statements, including comparatives, have been prepared in accordance with International Financial Reporting Standards ("IFRS") as issued by the International Accounting Standards Board ("IASB"), Interpretations issued by the International Financial Reporting Interpretations Committee ("IFRIC") and in accordance with International Accounting Standard ("IAS") 34 Interim Financial Reporting and which were in effect as of September 30, 2014.

Basis of Measurement

The financial statements have been prepared on an accrual basis and are based on historical costs. The financial statements are presented in Canadian dollars which is also the Company's functional currency.

These financial statements have been prepared on a going concern basis, which assumes that the Company will be able to realize its assets and discharge its liabilities in the normal course of business. As at September 30, 2014, the Company has not generated any revenues from operations, has an accumulated deficit of $132,488. The continued operations of the Company are dependent on its ability to generate future cash flows or obtain additional financing. Management is of the opinion that sufficient working capital will be obtained from external financing to meet the Company's liabilities and commitments as they become due, although there is a risk that additional financing will not be available on a timely basis or on terms acceptable to the Company. These financial statements do not reflect any adjustments that may be necessary if the Company is unable to continue as a going concern. These conditions indicate the existence of a material uncertainty that may cast significant doubt on the Company's ability to continue as a going concern.

Significant Estimates and Assumptions

The preparation of financial statements in accordance with IFRS requires the Company to make estimates and assumptions concerning the future. The Company's management reviews these estimates and underlying assumptions on an ongoing basis, based on experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances. Revisions to estimates are adjusted for prospectively in the period in which the estimates are revised.

Estimates and assumptions where there is significant risk of material adjustments to assets and liabilities in future accounting periods include the fair value measurements for financial instruments and the recoverability and measurement of deferred tax assets.

2. Basis of Preparation – (cont'd)

Significant Judgements

The preparation of financial statements in accordance with IFRS requires the Company to make judgments, apart from those involving estimates, in applying accounting policies. The most significant judgments in applying the Company's financial statements is the classification of financial instruments and the going concern assumption.

3. Significant Accounting Policies

The preparation of financial data is based on accounting principles and practices consistent with those used in the preparation of the audited financial statements as at March 31, 2014. The accompanying unaudited condensed interim financial statements should be read in conjunction with the Company's audited financial statements for the year ended March 31, 2014.

Intellectual properties

Intellectual properties consist of patents acquired externally and are recorded at cost less accumulated amortization and impairment losses.

Research costs are expensed as incurred. Development costs are expensed as incurred unless they meet certain criteria for deferral and amortization. The Company assesses whether it has met the relevant criteria for deferral and amortization at each reporting date.

Impairment of tangible and intangible assets

At the end of each reporting period, the Company's assets are reviewed to determine whether there is any indication that those assets may be impaired. If such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment, if any. The recoverable amount is the higher of fair value less costs to sell and value in use. Fair value is determined as the amount that would be obtained from the sale of the asset in an arm's length transaction between knowledgeable and willing parties. In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset. If the recoverable amount of an asset is estimated to be less than its carrying amount, the carrying amount of the asset is reduced to its recoverable amount and the impairment loss is recognized in profit or loss for the period. For an asset that does not generate largely independent cash flows, the recoverable amount is determined for the cash generating unit to which the asset belongs.

Where an impairment loss subsequently reverses, the carrying amount of the asset (or cash-generating unit) is increased to the revised estimate of its recoverable amount, but to an amount that does not exceed the carrying amount that would have been determined had no impairment loss been recognized for the asset (or cash-generating unit) in prior years. A reversal of an impairment loss is recognized immediately in profit or loss.

3. Significant Accounting Policies (cont'd)

Accounting standards issued but not yet applied

The following new standards and interpretations are not yet effective and have not been applied in preparing these financial statements. The Company is currently evaluating the potential impacts of these new standards and does not anticipate any material changes to the financial statements upon adoption of this new and revised accounting pronouncement.

- IFRS 9 – *Financial Instruments* (effective January 1, 2018) introduces new requirements for the classification and measurement of financial assets, and will replace IAS 39. IFRS 9 uses a single approach to determine whether a financial asset is measured at amortized cost or fair value, replacing the multiple classification options available in IAS 39.

4. Loan Receivables

On May 14, 2014 and July 8, 2014, the Company loaned $100,000 and $50,000, respectively, to Biomark Technologies Inc. ("Biomark Technologies"). On September 9, 2014, the Company advanced and additional $48,693 to Biomark Technologies to extinguish the assumed liabilities. These loans are non-interest bearing and are payable on demand.

5. Intellectual Properties

On September 5, 2014 and amended on September 8, 2014, the Company entered into an Asset Purchase Agreement with Biomark Technologies Inc. and Rashid Ahmed Bux ("Rashid") and Bux Investments Ltd. ("Bux") for the purchase of certain assets consisting of patents and an assumption of the assumed liabilities for the consideration of $800,000. The Company will issue to Biomark Technologies 40,000,000 common shares of the Company at a deemed value of $0.02 per share and assume the liabilities at the closing date. On September 29, 2014, the Company issued 40,000,000 common shares to Biomark Technologies.

6. Share Capital

a) Authorized

Unlimited common shares, without par value.

b) Issued

On February 27, 2014, the Company issued 2,000,000 common shares at a price of $0.005 per share for total proceeds of $10,000.

On March 31, 2014, the Company issued 4,600,000 common shares at a price of $0.02 per share for total proceeds of $92,000.

On April 29, 2014, the Company issued 500,000 common shares at a price of $0.02 per shares for total proceeds of $10,000.

On May 12, 2014, certain shareholders of the Company returned 2,200,000 common shares for cancellation for $nil consideration, accordingly, the Company recorded a gain of $34,704 to contributed surplus.

On September 29, 2014, the Company issued 40,000,000 common shares valued at $800,000 pursuant to the Asset Purchase Agreement.

c) Commitment to issue shares

As at September 30, 2014 the Company received $279,500 towards a private placement at $0.25 per share. The Company also paid finder's fee of $14,100 which is recorded as deferred finance cost.

7. Financial Instruments

The Company is exposed to varying degrees to a variety of financial instrument related risks:

Fair value

The carrying value of cash, loan receivable, accounts payable and accrued liabilities approximated their fair value because of the relatively short-term nature of these instruments.

Credit risk

The Company is exposed to credit risk with respect to its loan receivable. To reduce the credit risk of the loan receivable, the Company regularly reviews the collectability.

7. Financial Instruments (cont'd)

Interest rate risk

Interest rate risk is the risk the fair value or future cash flows of a financial instrument will fluctuate because of changes in market interest rates. Financial assets and liabilities with variable interest rates expose the Company to cash flow interest rate risk. The Company does not hold any financial liabilities with variable interest rates. The Company does maintain bank accounts which earn interest at variable rates but it does not believe it is currently subject to any significant interest rate risk.

Liquidity risk

The Company's ability to continue as a going concern is dependent on management's ability to raise required funding through future equity issuances and through short-term borrowing. The Company manages its liquidity risk by forecasting cash flows from operations and anticipating any investing and financing activities. Management and the Board of Directors are actively involved in the review, planning and approval of significant expenditures and commitments.

The Company intends to meet its current obligations in the following year with funds to be raised through private placements, shares for debt, loans and related party loans.

Fair value

Financial instruments measured at fair value are classified into one of three levels in the fair value hierarchy according to the relative reliability of the inputs used to estimate the fair values. The three levels of the fair value hierarchy are:

- Level 1 – Unadjusted quoted prices in active markets for identical assets or liabilities;
- Level 2 – Inputs other than quoted prices that are observable for the asset or liability either directly or indirectly; and
- Level 3 – Inputs that are not based on observable market data.

8. Capital Risk Management

The Company defines its capital as shareholders' equity. The Company's objectives when managing capital are to safeguard the Company's ability to continue as a going concern in order to pursue the development of its technologies and to maintain a flexible capital structure for its projects for the benefit of its stakeholders. As the Company is in the development stage, its principal source of funds is from the issuance of common shares.

The Company manages the capital structure and makes adjustments to it in light of changes in economic conditions and the risk characteristics of the underlying assets. To maintain or adjust the capital structure, the Company may attempt to issue new shares, acquire or dispose of assets or adjust the amount of cash.

The Company is not subject to externally imposed capital requirements.

9. Non-cash Transactions

Investing and financing activities that do not have a direct impact on cash flows are excluded from the statements of cash flows. The following transactions were excluded from the statement of cash flows:

During the period ended September 30, 2014:

- The Company issued 40,000,000 common shares valued at $800,000 pursuant to the terms of the Asset Purchase Agreement with Biomark Technologies Inc.

- Certain shareholders of the Company returned 2,200,000 common shares for cancellation for $nil consideration, accordingly, the Company recorded a gain of $34,704 to contributed surplus.

10. Subsequent Events

On October 3, 2014, the Company issued 1,478,000 common shares at a price of $0.25 per share for total proceeds of $369,500 and paid $14,100 in financing costs.

On October 15, 2014, the Company issued 557,040 common shares at a price of $0.25 per share for total proceeds of $139,260 and paid $3,600 in financing costs.